Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alvotech hands Fuji rights to Japan lines

Executive Summary

Alvotech has given Japanese firm Fuji Pharma exclusive commercial rights to its biosimilars portfolio in Japan. Under the deal, Alvotech will be responsible for developing and supplying biosimilars within its pipeline that currently includes rivals to AbbVie’s Humira (adalimumab) and Janssen’s Stelara (ustekinumab), the latter using perfusion fermentation technology.

You may also be interested in...

Alvotech And Fuji Pharma Broaden Biosimilar Alliance In Japan

Longtime partners Alvotech and Fuji Pharma – the latter being a minority shareholder in the Icelandic firm – have extended their existing biosimilars partnership in Japan, as Alvotech continues to make strategic moves across the globe.

Alvotech Moves Ahead On Higher-Concentration Humira Rival

Alvotech is moving ahead with developing its higher-concentration adalimumab biosimilar after completing enrollment in a European Phase III trial.

Alvotech And Fuji Stretch Alliance To Ustekinumab In Japan

Alvotech and Fuji Pharma have extended their alliance to cover exclusive development and supply of biosimilar ustekinumab in Japan. 

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts